Riskpilot← Back to searchSign inGet full accessCirqle Biomedical Contraception ApS
APSActiveCVR 39865769Ole Maaløes Vej 3, 3.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20182 employees
Revenue 2024
DKK 60,6M
-571% vs 2023
EBITDA margin
87.7%
+350% vs 2023
Equity ratio
91.0%
Financial strength
Net profit 2024
DKK 43,4M
+372% vs 2023
| Revenue | DKK 60,6M | -571% |
| EBITDA | DKK 53,2M | +350% |
| Net profit | DKK 43,4M | +372% |
| Total assets | DKK 39,5M | -14% |
| Equity | DKK 35,9M | +5% |
| Employees | 2 | — |
Legal name
Cirqle Biomedical Contraception ApS
CVR number
39865769
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11. september 2018
Share capital
DKK 45.059
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden og den administrerende direktør i forening, den administrerende direktør og et bestyrelsesmedlem i forening, eller to bestyrelsesmedlemmer og den administrerende direktør i forening.
Company purpose
Selskabets formål er at undersøge, udvikle og kommercialisere ny teknologi omkring præventionsmidler.
Address
Ole Maaløes Vej 3, 3.
Phone
+4526831750
Email
fm@cirqle.bio
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -4.133 | -5.769 | 62.142 | -12.848 | 60.579 |
| Staff expenses | -2.181 | -2.729 | -3.399 | -8.379 | -7.273 |
| EBITDA | -6.313 | -8.498 | 58.743 | -21.228 | 53.153 |
| Depreciation & amort. | -0 | -0 | -0 | -8 | -55 |
| EBIT | -6.313 | -8.498 | 58.743 | -21.236 | 53.098 |
| Net financials | -401 | -283 | -375 | 448 | 2.275 |
| Profit before tax | -6.715 | -8.781 | 58.368 | -20.788 | 55.372 |
| Tax | -1.157 | -1.573 | 10.686 | -4.803 | 11.947 |
| Net profit | -5.558 | -7.208 | 47.682 | -15.985 | 43.425 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 10.783 | 3.628 | 70.219 | 45.936 | 39.476 |
| Equity | 2.844 | -4.364 | 50.351 | 34.366 | 35.931 |
| Long-term debt | 7.001 | 7.129 | 7.477 | 8.069 | 0 |
| Short-term debt | 938 | 864 | 12.391 | 3.500 | 3.539 |
| Total debt | 7.938 | 7.992 | 19.868 | 11.569 | 3.539 |
EBITDA margin
87.7%
This company
15.8%
Market median
+455% vs market
20202024
Equity ratio
91.0%
This company
38.2%
Market median
+138% vs market
20202024
Return on equity
120.9%
This company
18.4%
Market median
+557% vs market
20202024
Net profit margin
71.7%
This company
8.1%
Market median
+785% vs market
20202024
Asset turnover
1.53×
This company
1.12×
Market median
+37% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TC Management | Management | 2018 |
FP Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2018 | |
| Individual | 5–9.99% | 5–9.99% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FREDERIK MADSEN HOLDING ApSCirqle Biomedical Holding ApS
Cirqle Biomedical Contraception ApS (this company)Board members of Cirqle Biomedical Contraception ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Crouzier | Management | 0 companies |
| Frederik Petursson Madsen | Chief Executive Officer | 0 companies |
| Jesper Boysen | Chairman | 0 companies |